Slides
Page 1
Financial results of the Diagnostyka Group for Q2 2026 11 September 2026
Page 2
Jakub Swadźba President of the Management Board, Chief Executive Officer (CEO) Bartosz Cieślicki Deputy Chief Financial Officer Presenters: Jakub Tatak Vice President of the Management Board, Chief Financial Officer (CFO)
Page 3
Key developments in Q2 2026
Page 4
Appointment of Jakub Tatak as Member of the Management Board and Chief Financial Officer as of 1 September 2026 Q2 2026 summary Diagnostic tests volume 45.5 million (up 4.1% y/y) Revenue from contracts with customers PLN 683.0 million (up 16.1% y/y) Net profit attributable to owners of the Parent PLN 57.4 million (down 10.1% y/y) Recurring EBITDA¹ PLN 154.4 million (up 1.0% y/y) ¹ The Group defines EBITDA as net profit (loss) adjusted for income tax, share of profit or loss of associates or jointly con trolled entities, impairment losses on investments in associates and jointly controlled entities for the period, finance costs, finance income, depreciation and amortisation. Recurring EBITDA is defined as EBITDA additionally adjusted for IPO costs, the IPO -linked share-based payment plan and other one-off items (e.g. transaction advisory fees). Financial highlights Dividend paid by the Company for 2025 PLN 148.5 million (PLN 4.40 per share) Medical laboratory testing services 2 acquisitions in Q2 2026 (8 acquisitions in H1 2026) Penta Hospitals Poland Increased contract value (tender awarded in July 2026) Diagnostic imaging 1 acquisition in Q2 2026 (3 acquisitions in H1 2026 ) NFZ regulatory changes Full reimbursement of above- limit MRI and CT scan procedures for cancer patients undergoing follow-up treatment Operational highlights
Page 5
Financial performance
Page 6
Dominant share of the MLT market in the Group’s revenue in Q2 2026 MLT 94.0% DI 6.0% 1.5% 98.5% Q4 2024 4.1% 95.9% Q1 2025 4.7% 95.3% Q2 2025 5.6% 94.4% Q3 2025 6.1% 93.9% Q4 2025 6.3% 93.7% Q1 2026 6.0% 94.0% Q2 2026 505 592 588 612 618 671 683 DI – diagnostic imaging services market MLT – medical laboratory testing market Revenue from contracts with customers (PLN million) and share of the MLT and DI markets in the Group’s revenue MLT 94.0%
Page 7
Strong revenue growth driven by organic expansion Revenue from contracts with customers (PLN million) 37,0% 62,7% B2C B2B 35,7% 64,2% B2C B2B 215,7 243,1 237,8 2.2 Q2 2025 4.9 Q1 2026 5.8 Q2 2026 217.9 248.0 243.6 +11.8% 440,3 480,9 4.7 H1 2025 10.7 H1 2026 444.9 491.6 +10.5% 343,6 384,7 403,3 25.4 Q2 2025 37.1 Q1 2026 35.0 Q2 2026 369.0 421.8 438.2 +18.8% 685,0 788,0 47.1 H1 2025 72.0 H1 2026 732.1 860.0 +17.5% Revenue mix: B2C revenue B2B revenue 560,7 629,0 642,2 27.6 Q2 2025 41.9 Q1 2026 40.8 Q2 2026 588.3 670.9 683.0 +16.1% 1128,1 1271,2 51.8 H1 2025 82.7 H1 2026 1,179.9 1,353.9 +14.8% + ROBUST REVENUE GROWTH The Group continued to deliver strong revenue growth, with revenue up 16.1% y/y (including 14.5% in MLT) in Q2 2026 and 14.8% y/y (including 12.7% in MLT) in H1 2026. Organic expansion was the main driver of the strong y/y revenue performance in MLT, both in Q2 2026 and across H1 2026. + B2B SEGMENT AS A KEY GROWTH DRIVER B2B revenue rose by 18.8% y/y in Q2 2026 and by 17.5% in H1 2026, bringing the segment’s share of total revenue to 64.2% in Q2 2026. + STRONG MOMENTUM IN DIAGNOSTIC IMAGING (DI) Progress in delivering the strategic objectives for this area translated into revenue growth of 47.8% y/y in Q2 2026 and 59.7% y/y in H1 2026, to PLN 82.7 million. DI – diagnostic imaging market MLT – medical laboratory testing market MLT: +9.2% MLT: +15.1% Q2 2025 Q2 2026 MLT: +12.7% MLT: +14.5% MLT: +10.2% MLT: +17,4%
Page 8
Test volume (million) 14,8% 85,2% Q2 2025 B2C B2B 14,8% 85,2% Q2 2026 B2C B2B 6,5 6,9 6,7 0.004 Q2 2025 0.010 Q1 2026 0.011 Q2 2026 13,4 13,6 0.009 H1 2025 0.021 H1 2026 37,1 38,7 38,5 0.131 Q2 2025 0.179 Q1 2026 0.177 Q2 2026 75,3 77,2 0.267 H1 2025 0.355 H1 2026 Volume mix B2C volume (million) B2B volume (million) Revenue growth driven by both volume and pricing + ACCELERATION IN VOLUME GROWTH IN Q2 2026 Following a temporary slowdown in Q1 2026, resulting from a high comparative base (the impact of the Profilaktyka 40 PLUS programme in 2025) and unfavourable weather conditions, the Group saw a marked improvement in Q2 2026. Test volume growth accelerated from 1.2% y/y in Q1 2026 to 4.1% y/y in Q2 2026. + HIGHER AVERAGE PRICE IN DI The 17.0% y/y increase in H1 2026 reflected a shift in the sales mix, with a reduced share of teleradiology services, which have lower selling prices. Average price* Q2 2025 MLT 12.8 DI** 204.4 Q1 2026 Q2 2026 change y/y (%) H1 2025 H1 2026 change y/y (%) 13.8 14.2 10.2% 12.7 14.0 10.0% 222.2 217.1 6.2% 187.8 219.7 17.0% Average 13.4 14.6 15.0 11.6% 13.2 14.8 11.9% * Excluding sales of goods ** Including teleradiology interpretation and reporting services DI – diagnostic imaging services market MLT – medical laboratory testing market 6.5 6.9 6.7 +4.5% 37.2 38.9 38.7 +4.0% 13.4 13.7 +2.2% 75.5 77.6 +2.7% 43.7 45.8 45.5 +4.1% 43,5 45,6 45,3 0.135 Q2 2025 0.189 Q1 2026 0.188 Q2 2026 88.9 91.3 +2.6% 88,6 90,9 0.276 H1 2025 0.377 H1 2026
Page 9
Structure of operating expenses 490,6 558,5 591,2 Q2 2025 Q1 2026 Q2 2026 973,2 1 149,7 H1 2025 H1 2026 Operating expenses (PLN million) y/y growth of operating expenses (%): y/y growth of revenue from contracts with customers (%): 20.5% 16.1% 18.1% 14.8% + STABILISATION OF THE NEW ERP SYSTEM (SAP) The new ERP system (SAP) went live in January 2026, requiring further fine-tuning and optimisation of operating processes. In Q2 2026, work focused on completing the process of resolving system issues and conducting inventory checks to verify material consumption. + INCREASE OF PLN 176.5 MILLION IN OPERATING EXPENSES IN H1 2026 VS H1 2025: RAW MATERIALS AND CONSUMABLES USED (UP PLN 47.4 MILLION Y/Y) The settlement of inventory discrepancies for the first half of the year, along with the adjustment of warehouse processes to the new ERP system (SAP), weighed on the raw materials and energy line in Q2'26. This was a one-off balance sheet adjustment. SERVICES (UP PLN 37.8 MILLION Y/Y) The strong increase in this cost category (up 22.6% y/y in H1 2026) was driven by the consolidation of the diagnostic imaging business and strategic investment in digital transformation (including the SAP implementation and development of cloud services). Operating expenses excl. one-off items (PLN million) Q2 2025 Q2 2026 Q2 2026 vs Q2 2025 (%) *share of Q2 2025 revenue H1 2025 H1 2026 H1 2026 vs H1 2025 (%) *share of H1 2025 revenue Depreciation and amortisation 50.1 59.3 18.3% 8.5% 97.2 115.9 19.2% 8.2% Raw materials and energy 119.4 151.1 26.5% 20.3% 241.1 288.5 19.7% 20.4% Services 85.8 108.2 26.0% 14.6% 167.0 204.8 22.6% 14.2% Employee benefits expense 220.8 254.1 15.1% 37.5% 438.2 506.4 15.6% 37.1% Taxes and charges 7.4 8.7 18.6% 1.3% 14.6 17.9 22.7% 1.2% Cost of goods for resale and materials sold 1.2 1.1 -12.0% 0.2% 2.5 2.2 -11.9% 0.2% Other 5.8 8.7 50.7% 1.0% 10.8 13.9 29.0% 0.9% TOTAL 490.6 591.2 20.5% 83.4% 971.3 1,149.7 18.4% 82.3% *share of Q2 ’26 revenue *share of H1 2026 revenue 8.7% 8.6% 22.1% 21.3% 15.8% 15.1% 37.2% 37.4% 1.3% 1.3% 0.2% 0.2% 1.3% 1.0% 86.6% 84.9% 15.7% 13.4% 21.5% 22.3% 22.8% 22.7% Q1 2026 56.6 137.5 96.6 252.3 9.1 1.1 5.3 558.5 * Revenue from contracts with customers
Page 10
314,1 174,1 2,2 4,3 334,0 Recurring EBITDA H1 2025 Revenue from contracts with customers Raw materials and energy Purchase of analytical services Purchase of diagnostics- related services IT services Other services Employee benefits expense Fair value measurement of shares (equity method → full consolidation) Other expenses and income Recurring EBITDA H1 2026 -47.5 -21.4 -9.4 -9.3 -68.3 -4.9 Recurring EBITDA: H1 2025 vs H1 2026 (PLN million) Change as % of revenue from contracts with customers: -0.9% 0.3% -0.8% -0.6% 0.1% -0.3% Recurring EBITDA margin: 26.6% 24.7% Recurring EBITDA at PLN 334.0 million in H1 2026, up 6.3% y/y 152,9 179,6 154,4 Q2 2025 Q1 2026 Q2 2026 +1.0% 314,1 334,0 H1 2025 H1 2026 +6.3% Recurring EBITDA margin (%): 26.0% 26.8% Recurring EBITDA (PLN million) Services + Q2 2026 margin affected by SAP system stabilisation costs + Other operating income in H1 2026 was supported by a PLN 4.3 million gain on fair value measurement of shares on acquiring control of a jointly controlled entity + Net of the gain on the share measurement, recurring EBITDA for H1 2026 is PLN 329.7 million (vs the reported PLN 334.0 million), with recurring EBITDA margin at 24.4% (vs the reported margin 24.7%) + The decline in recurring EBITDA margin in H1 2026 was due mainly to higher operating expenses, including costs of raw materials as well as purchases of analytical diagnostic services and IT services in connection with the Group’s development and increasing share of the diagnostic imaging segment -0.1% 26.6%22.6% 24.7% 0.3%
Page 11
PLN 139.9 million net profit attributable to owners of the Parent Q2 2025 Recurring EBITDA 152.9 Recurring EBITDA margin 26.0% Q2 2026 Change y/y % change y/y H1 2025 Change y/y % change y/y 154.4 1.5 1.0% 314.1 19.9 6.3% 22.6% -3.4% 26.6% -2.0% One-off costs 0.0 0.0 0.0 -100.0% -1.9 1.9 Depreciation and amortisation -50.1 -59.3 -9.2 18.3% -97.2 -18.7 19.2% EBIT 102.8 95.1 -7.7 -7.5% 215.0 3.1 1.4% EBIT margin 17.5% 13.9% -3.6% 18.2% -2.1% Finance income 0.7 0.8 0.1 13.1% 1.4 1.0 71.6% Finance costs -16.8 -16.2 0.5 -3.3% -33.0 -0.5 1.4% Share of profit or loss of associates and jointly controlled entities -0.2 -0.4 -0.3 143.8% 0.2 -0.1 -39.1% Income tax -19.8 -18.7 1.0 -5.2% -41.8 0.9 -2.2% Net profit 66.8 60.5 -6.3 -9.4% 141.9 4.5 3.2% Net profit margin 11.3% 8.9% -2.5% 12.0% -1.2% Net profit attributable to owners of the Parent 63.8 57.4 -6.4 -10.1% 136.7 3.3 2.4% Net profit attributable to non-controlling interests 2.9 3.1 0.1 3.9% 5.2 1.2 23.7% H1 2026 334.0 24.7% 0.0 -115.9 218.1 16.1% 2.5 -33.5 0.1 -40.9 146.4 10.8% 139.9 6.4 Key factors driving net profit growth in H1 2026 vs H1 2025 (up PLN 4.5 million y/y): + No one-off IPO costs in H1 2026 + PLN 18.7 million y/y increase in depreciation and amortisation, driven by the Group’s continued expansion and investments in IT infrastructure and systems, as well as the recognition of new lease contracts + PLN 1.0 million y/y increase in finance income, due mainly to higher interest on loans to associates + PLN 0.5 million y/y decrease in finance costs, chiefly as a result of lower interest on borrowings following interest rate cuts -100.0%
Page 12
Robust cash flow supporting the Group's further growth 164,1 139,1 122,9 Q2 2025 Q1 2026 Q2 2026 -25.1% 107.3% 37,6 27,7 39,3 35,4 31,9 Q2 2025 Q1 2026 9.2 Q2 2026 73.0 59.6 48.5 Capex (PLN million) 18,4 17,6 239,8 334,0 262,0 153,9 107,2 4,6 222,3 Cash at the beginning of the period EBITDA Income tax paid Change in NWC FCF Capex excl. M&A Available cash Available financing Cash at the end of the period OtherDividends paid Interest on borrowings BorrowingsLease cash flows Disbursem ents of loans FCF less capex -33.6 -38.4 M&A capex -41.1 -10.6 -87.0 -14.4 -154.5 -67.0 78.4% M&A Capex excl. M&A 70,0 67,0 36,3 41,1 H1 2025 H1 2026 106.4 108.1 294,3 262,0 H1 2025 H1 2026 -11.0% H1 2026 cash flow (PLN million) FCF/EBITDA 77.4% 79.6% 6.4%Capex excl. M&A/revenue 4.1% 5.8% 5.9% Free cash flow (PLN million) ¹ FCF: the Company defines free cash flow as EBITDA less: (i) income tax paid; and (ii) adjustments resulting from changes in working capital disclosed in the consolidated statement of cash flows ² Revenue from contracts with customers ³ Change in net working capital IT INVESTMENTS: 30.2 million in H1 2025 vs 33.2 million in H1 2026 INVESTMENTS IN THE NETWORK OF LABORATORIES AND BLOOD COLLECTION POINTS 37.6 million in H1 2025 vs 30.7 million in H1 2026 INVESTMENTS AT DIAGNOSTIC IMAGING COMPANIES 2.2 million in H1 2025 vs 3.1 million in H1 2026 94.2% 78.4% 4.9%
Page 13
Working-capital turnover (days) Q2 2025 DIO – Days Inventory Outstanding 36.2 DSO – Days Sales Outstanding 62.7 Q1 2026 43.1 62.1 DPO – Days Payable Outstanding 51.7 53.6 CCC – Cash Conversion Cycle 47.1 51.6 627,2 632,3 742,7 396,0 473,6 478,8 -41.2 Q2 2025 -35.6 Q1 2026 -17.6 Q2 2026 981.9 1.070,3 1.203,9 Net debt/LTM EBITDA 1.8 1.8 2.0 62,8 58,0 243,7 323,5 345,8 -120,7 -143,6 -160,4 49.4 Q2 2025 Q1 2026 Q2 2026 172.5 242.6 243.5 +41.2% Net working capital* (PLN million) Trade receivables Inventories Trade payables Leases Financial debt (bank borrowings) Cash Net debt (PLN million) Q2 2026 36.4 69.5 53.3 52.5 Net debt and working capital under control + Net working capital up PLN 71.0 million year on year in Q2 2026, with the increase due to a PLN 102.1 million growth in receivables, mainly as a result of higher sales + Increase in net debt to PLN 1,203.9 million, driven by higher lease liabilities (up PLN 82.8 million) and bank borrowings (upPLN 115.6 million); the increase in lease liabilities mainly reflects the recognition of the SAP system as a new right-of-use asset and the extension of the laboratory equipment lease Change y/y 0.2 6.8 1.6 5.3 * Net working capital comprises inventories, trade receivables and trade payables
Page 14
2026 outlook for the Diagnostyka Group Revenue from contracts with customers low/mid teens % y/y growth Average price per test high single digit % y/y growth Recurring EBITDA margin close to 2025 Capex excl. M&A PLN 170-220 million M&A capex PLN 50-100 million Net debt/ EBITDA 1,7-2,0x Test volume low/mid single digit % y/y growth
Page 15
Appendices
Page 16
Half-year condensed consolidated statement of comprehensive income (PLN thousand) Half-year condensed consolidated statement of financial position (PLN thousand) H1 2026 Revenue 1,367,798 Revenue from contracts with customers 1,353,932 H1 2025 Change (%) Q2 2026 Q2 2025 Change (%) 1,188,224 15% 686,240 593,374 15.7% 1,179,855 15% 683,016 588,303 16.1% Other operating income 13,866 8,369 66% 3,224 5,071 -36.4% Operating expenses -1,149,651 -973,194 18% -591,158 -490,574 20.5% Depreciation and amortisation -115,858 -97,204 19% -59,294 -50,121 18.3% Raw materials and consumables used -288,549 -241,074 20% -151,092 -119,441 26.5% Services -204,835 -166,809 23% -108,196 -85,815 26.1% Employee benefits expense -506,406 -440,228 15% -254,082 -220,835 15.1% Taxes and charges -17,856 -14,556 23% -8,732 -7,365 18.6% Other expenses by nature -11,630 -8,769 33% -7,788 -5,079 53.3% Cost of goods for resale and materials sold -2,227 -2,528 -12% -1,095 -1,243 -11.9% Impairment losses (including reversals of impairment losses) on trade receivables and other financial assets -903 2 -45250% -177 394 -144.9% Other operating expenses -1,387 -2,028 -32% -702 -1,069 -34.3% Operating profit (loss) 218,147 215,030 1% 95,082 102,800 -7.5% Finance income 2,457 1,432 72% 798 706 13.0% Finance costs -33,454 -32,996 1% -16,248 -16,797 -3.3% Share of profit or loss of associates and jointly controlled entities 125 205 -39% -444 -182 144.0% Profit (loss) before tax 187,275 183,671 2% 79,188 86,527 -8.5% Income tax (40,897) (41,805) -2% (18,735) (19,772) -5.2% NET PROFIT (LOSS) 146,378 141,866 3% 60,453 66,755 -9.4% Net profit attributable to: Owners of the Parent 139,947 136,668 2.4% 57,393 63,809 -10.1% Non-controlling interests 6,431 5,198 24% 3,060 2,946 3.9% Earnings per share attributable to owners of the Parent: Basic earnings per share 4.1 4.0 2.4% 1.7 1.9 -10.1% Diluted earnings per share 4.1 4.0 2.4% 1.7 1.9 -10.1% ASSETS As at 30 Jun 2026 Non-current assets 1,776,105 Property, plant and equipment 515,891 As at 31 Dec 2025 Change (%) 1,700,850 4% 514,095 0% Right-of-use assets 490,452 459,489 7% Goodwill 496,604 478,091 4% Other intangible assets 187,076 174,574 7% Loans granted 36,643 29,199 25% Investments in associates and jointly controlled entities 39,034 36,321 7% Deferred tax assets 1,815 2,309 -21% Non-current receivables 6,994 5,526 27% Derivative instruments 0 0 n.a. Non-current prepayments and accrued income 1,596 1,246 28% Current assets 455,776 368,688 24% Inventories 57,986 68,737 -16% Trade receivables 345,842 258,281 34% Current tax assets 588 437 35% Loans granted 6,475 4,052 60% Public charges receivable 192 551 -65% Other current receivables 9,074 7,812 16% Derivative instruments 0 1,765 -100% Current prepayments and accrued income and other assets 18,055 8,629 Cash and cash equivalents 17,564 18,424 -5% TOTAL ASSETS 2,231,881 2,069,538 8% 109% EQUITY AND LIABILITIES As at 30 Jun 2026 Equity 527,321 Share capital 33,757 As at 31 Dec 2025 Change (%) 547,192 -4% 33,757 0% Share premium 41,617 41,617 0% Capital reserve 305,845 207,762 47% Retained earnings 243,093 349,758 -30% Other reserves -114,414 -104,497 9% Equity attributable to owners of the Parent 509,898 528,397 -4% Equity attributable to non-controlling interests Non-current liabilities 1,145,239 1,015,583 13% Bank borrowings 735,417 627,714 17% Lease liabilities 344,810 305,243 13% Other financial liabilities 39,081 50,226 -22% Employee benefit obligations 3,830 3,830 0% Deferred tax liabilities 17,576 24,024 -27% Other liabilities and government grants 4,525 4,546 0% Current liabilities 559,321 506,763 10% Trade payables 160,356 134,960 19% Bank borrowings 7,311 6,085 20% Lease liabilities 133,971 141,602 -5% Other financial liabilities 64,642 58,875 10% Current tax liabilities 21,678 7,431 Employee benefit obligations 93,070 83,158 12% Public charges payable 53,522 49,583 8% 192% 17,423 18,795 -7% Other liabilities and government grants 24,771 25,069 -1% TOTAL EQUITY AND LIABILITIES 2,231,881 2,069,538 8%
Page 17
Half-year condensed consolidated statement of cash flows (PLN thousand) 1 Jan–30 Jun 2026 Profit (loss) before tax 187,275 Adjustments to profit before tax: 147,691 1 Jan–30 Jun 2025 183,670 129,416 Share of profit or loss of associates and jointly controlled entities -125 -205 Depreciation and amortisation 115,858 97,204 (Gain)/loss on investing activities -4,463 -4,154 Net finance income/(costs) 31,653 32,035 Share-based payment plan 4,768 4,536 Adjustments due to changes in net working capital: -38,398 149 (Increase)/decrease in trade and other receivables -85,784 -19,028 (Increase)/decrease in inventories 10,985 -3,969 Increase/(decrease) in liabilities, excluding borrowings 46,029 32,063 Change in accruals and deferrals -9,628 -8,917 Income tax paid -33,650 -18,132 Net cash flows from operating activities 262,918 295,103 Cash flows from investing activities Proceeds from sale of property, plant and equipment and intangible assets 1,163 Payments to acquire property, plant and equipment and intangible assets -67,007 6,883 -70,049 Proceeds from sale of investments in associates -0 35 Payments to acquire subsidiary and businesses, net of cash acquired -36,342 -34,713 Payments to acquire shares of jointly controlled entities and associates -4,733 -1,627 Proceeds from sale of subsidiary, net of cash disposed of -0 -0 Dividends received 350 319 Interest received 33 1 Repayments of loans 2,036 -0 Net cash flows from investing activities -115,144 -116,407 Cash flows from financing activities Non-controlling interest in capital increase at subsidiaries 30 Acquisition of non-controlling interests 0 4,925 -2,220 Cash flows from derivative instruments (IRS) 1,900 3,854 Repayments of the principal portion of lease liabilities -71,177 -64,043 Proceeds from borrowings 121,454 52,100 Repayments of borrowings -14,209 -24,404 Interest on lease liabilities -15,859 -11,321 Interest on borrowings -16,290 -19,930 Dividends paid to owners of the Parent -148,529 -111,734 Dividends paid to non-controlling interests -5,954 -5,251 Net cash flows from financing activities -148,634 -178,024 Net increase (decrease) in cash and cash equivalents -860 672 Cash at the beginning of the period 18,424 40,518 Cash at the end of the period 17,564 41,190 1 Jan–30 Jun 2026 1 Jan–30 Jun 2025 Disbursements of loans -10,644 -17,256
Page 18
Contact Michał Błasiński Investor Relations Director michal.blasinski@diag.pl This presentation (the “Presentation”) has been prepared by Diagnostyka S.A. (“Diagnostyka”) to share selected information about the Diagnostyka Group (“Diagnostyka Group”) with shareholders, analysts, business partners and other stakeholders. It is for information purposes only and does not purport to provide a comprehensive analysis of the Group’s financial position. While the information contained herein has been presented with due care, some data may have been obtained from external sources and have not been properly verified. No representations or warranties can be made as to the accuracy or completeness of the information contained in this Presentation. Please note that the information in this Presentation is indicative only and does not reflect all circumstances affecting the final results for the period, which may differ materially from the figures presented. This Presentation should not be relied upon in making decisions regarding the purchase or sale of Diagnostyka shares or related derivative instruments. Diagnostyka shall have no liability for any decisions made on the basis of this Presentation. Recipients of this Presentation are advised to monitor the final results, which are published in periodic reports together with the accompanying review reports prepared by an independent auditor. For information regarding the Company, please refer to its periodic and current reports published in accordance with applicable Polish laws. Disclaimer